THC Stock Recent News

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Tenet (THC) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Tenet (THC) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices. It is one of the several stocks that made it through our 'Fast-Paced Momentum at a Bargain' screen.

Tenet Healthcare (THC) shares soared to a more than two-decade high after the hospital and surgical center chain posted stronger-than-expected results and boosted its outlook as it brought in more patients who paid more for services.

Tenet Healthcare's (THC) Q2 results reflect net revenue per case growth, higher pricing yield and a decline in overall expenses. It expects 2024 adjusted EPS within $10.41-$11.12, up from the previous guidance of $8.37-$9.41.

While the top- and bottom-line numbers for Tenet (THC) give a sense of how the business performed in the quarter ended June 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

On Wednesday, Tenet Healthcare Corporation THC reported first-quarter sales of $5.37 billion, up around 7% year over year, beating the consensus of $5.15 billion.

Tenet Healthcare (THC) came out with quarterly earnings of $2.31 per share, beating the Zacks Consensus Estimate of $1.89 per share. This compares to earnings of $1.44 per share a year ago.

Tenet (THC) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

WGS, THC and APOG made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on July 23, 2024.